Patients receiving Exparel required significantly fewer pain pills than those who received a placebo. Exparel also provided pain relief for at least 48 hours, according to the report. The study was conducted on 193 patients who had bunions removed from their feet.
The FDA has set a July 28 deadline for deciding whether the drug can be sold in the United States.
Read the Sign On San Diego report on Exparel.
Read more on anesthesia:
–Johnson & Johnson and FDA Clash Over Rejection of Sedative
–50% of Pediatric Patient Parents Do Not Understand the Risks or Benefits of Anesthesia
